Study on retroperitoneal liposarcoma: current status and challenge

doi:10.16139/j.1007-9610.2022.06.08

Abstract

CLC Number:

XIE Fuan, REN Yantao, LI Wengang. Study on retroperitoneal liposarcoma: current status and challenge[J]. Journal of Surgery Concepts & Practice, 2022, 27(06): 521-525.

References 40

[1]	Gatta G, van der Zwan JM, Casali PG, et al. Rare cancers are not so rare: the rare cancer burden in Europe[J]. Eur J Cancer, 2011, 47(17):2493-2511. doi: 10.1016/j.ejca.2011.08.008 pmid: 22033323
[2]	Lee ATJ, Thway K, Huang PH, et al. Clinical and molecular spectrum of liposarcoma[J]. J Clin Oncol, 2018, 36(2):151-159. doi: 10.1200/JCO.2017.74.9598 pmid: 29220294
[3]	Bonvalot S, Raut CP, Pollock RE, et al. Technical considerations in surgery for retroperitoneal sarcomas: position paper from E-Surge, a master class in sarcoma surgery, and EORTC-STBSG[J]. Ann Surg Oncol, 2012, 19(9):2981-2991. doi: 10.1245/s10434-012-2342-2 pmid: 22476756
[4]	Gahvari Z, Parkes A. Dedifferentiated liposarcoma: systemic therapy options[J]. Curr Treat Options Oncol, 2020, 21(2):15. doi: 10.1007/s11864-020-0705-7 URL
[5]	Matushansky I, Hernando E, Socci ND, et al. A deve-lopmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas[J]. Am J Pathol, 2008, 172(4):1069-1080. doi: 10.2353/ajpath.2008.070284 pmid: 18310505
[6]	Cancer Genome Atlas Research Network. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas[J]. Cell, 2017, 171(4):950-965. doi: S0092-8674(17)31203-5 pmid: 29100075
[7]	Shimada S, Ishizawa T, Ishizawa K, et al. The value of MDM2 and CDK4 amplification levels using real-time polymerase chain reaction for the differential diagnosis of liposarcomas and their histologic mimickers[J]. Hum Pathol, 2006, 37(9):1123-1129. pmid: 16938516
[8]	Zhu H, Gao H, Ji Y, et al. Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials[J]. J Hematol Oncol, 2022, 15(1):91. doi: 10.1186/s13045-022-01314-3 URL
[9]	Ozenne P, Eymin B, Brambilla E, et al. The ARF tumor suppressor: structure, functions and status in cancer[J]. Int J Cancer, 2010, 127(10):2239-2247. doi: 10.1002/ijc.25511 pmid: 20549699
[10]	Cissé MY, Pyrdziak S, Firmin N, et al. Targeting MDM2-dependent serine metabolism as a therapeutic strategy for liposarcoma[J]. Sci Transl Med, 2020, 12(547): eaay2163.
[11]	Casadei L, de Faria FCC, Lopez-Aguiar A, et al. Targetable pathways in the treatment of retroperitoneal liposarcoma[J]. Cancers (Basel), 2022, 14(6):1362. doi: 10.3390/cancers14061362 URL
[12]	Dickson MA, Schwartz GK, Keohan ML, et al. Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: a phase 2 clinical trial[J]. JAMA Oncol, 2016, 2(7):937-940. doi: 10.1001/jamaoncol.2016.0264 pmid: 27124835
[13]	Lee SE, Kim YJ, Kwon MJ, et al. High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma[J]. Histol Histo-pathol, 2014, 29(1):127-138.
[14]	Italiano A, Bianchini L, Gjernes E, et al. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas[J]. Clin Cancer Res, 2009, 15(18):5696-5703. doi: 10.1158/1078-0432.CCR-08-3185 pmid: 19737942
[15]	Thirasastr P, Somaiah N. Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dediffe-rentiated liposarcoma[J]. Ther Adv Med Oncol, 2022, 14:17588359221081073.
[16]	Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data[J]. Cancer Discov, 2012, 2(5):401-404. doi: 10.1158/2159-8290.CD-12-0095 pmid: 22588877
[17]	Xi Y, Shen W, Ma L, et al. HMGA2 promotes adipoge-nesis by activating C/EBPβ-mediated expression of PPARγ[J]. Biochem Biophys Res Commun, 2016, 472(4):617-623. doi: 10.1016/j.bbrc.2016.03.015 URL
[18]	Nishino J, Kim I, Chada K, et al. Hmga2 promotes neural stem cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf Expression[J]. Cell, 2008, 135(2):227-239. doi: 10.1016/j.cell.2008.09.017 pmid: 18957199
[19]	Narita M, Narita M, Krizhanovsky V, et al. A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation[J]. Cell, 2006, 126(3):503-514. doi: 10.1016/j.cell.2006.05.052 pmid: 16901784
[20]	Barretina J, Taylor BS, Banerji S, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy[J]. Nat Genet, 2010, 42(8):715-721. doi: 10.1038/ng.619 pmid: 20601955
[21]	Serna VA, Kurita T. Patient-derived xenograft model for uterine leiomyoma by sub-renal capsule grafting[J]. J Biol Methods, 2018, 5(2):e91. doi: 10.14440/jbm.2018.243 URL
[22]	Miyake K, Higuchi T, Oshiro H, et al. The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model[J]. Biomed Pharmacother, 2019, 117:109093. doi: 10.1016/j.biopha.2019.109093 URL
[23]	Loewenstein S, Lubezky N, Nizri E, et al. Adipose-induced retroperitoneal soft tissue sarcoma tumorigenesis: a potential crosstalk between sarcoma and fat cells[J]. Mol Cancer Res, 2016, 14(12):1254-1265. pmid: 27621268
[24]	Peng T, Zhang P, Liu J, et al. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors[J]. Lab Invest, 2011, 91(3):392-403. doi: 10.1038/labinvest.2010.185 pmid: 21060307
[25]	Xie F, Qin D, Lian L, et al. Establishment of an orthotopic perirenal space xenograft mouse model of retroperitoneal sarcoma[J]. Cancer Commun (Lond), 2021, 41(7):631-634.
[26]	Wu JW, Preuss C, Wang SP, et al. Epistatic interaction between the lipase-encoding genes Pnpla2 and Lipe causes liposarcoma in mice[J]. PLoS Genet, 2017, 13(5):e1006716. doi: 10.1371/journal.pgen.1006716 URL
[27]	Bi P, Yue F, Karki A, et al. Notch activation drives adipocyte dedifferentiation and tumorigenic transformation in mice[J]. J Exp Med, 2016, 213(10):2019-2037. doi: 10.1084/jem.20160157 URL
[28]	Gutierrez A, Snyder EL, Marino-Enriquez A, et al. Aberrant AKT activation drives well-differentiated liposarcoma[J]. Proc Natl Acad Sci U S A, 2011, 108(39):16386-16391. doi: 10.1073/pnas.1106127108 URL
[29]	Liberti DC, Morrisey EE. Organoid models: assessing lung cell fate decisions and disease responses[J]. Trends Mol Med, 2021, 27(12):1159-1174. doi: 10.1016/j.molmed.2021.09.008 pmid: 34674972
[30]	Li M, Jiang F, Xue L, et al. Recent progress in biosensors for detection of tumor biomarkers[J]. Molecules, 2022, 27(21):7327. doi: 10.3390/molecules27217327 URL
[31]	Li S, He M, Lei Y, et al. Oral microbiota and tumor-a new perspective of tumor pathogenesis[J]. Microorganisms, 2022, 10(11):2206. doi: 10.3390/microorganisms10112206 URL
[32]	Suárez B, Solé C, Márquez M, et al. Circulating micro-RNAs as cancer biomarkers in liquid biopsies[J]. Adv Exp Med Biol, 2022, 1385:23-73.
[33]	Hirata M, Asano N, Katayama K, et al. Integrated exome and RNA sequencing of dedifferentiated liposarcoma[J]. Nat Commun, 2019, 10(1):5683. doi: 10.1038/s41467-019-13286-z pmid: 31831742
[34]	Liu W, Tong H, Zhang C, et al. Integrated genomic and transcriptomic analysis revealed mutation patterns of de-differentiated liposarcoma and leiomyosarcoma[J]. BMC Cancer, 2020, 20(1):1035. doi: 10.1186/s12885-020-07456-2 pmid: 33115433
[35]	Beird HC, Wu CC, Ingram DR, et al. Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin[J]. Cold Spring Harb Mol Case Stud, 2018, 4(2):a002386. doi: 10.1101/mcs.a002386 URL
[36]	Egan JB, Barrett MT, Champion MD, et al. Whole genome analyses of a well-differentiated liposarcoma reveals novel SYT1 and DDR2 rearrangements[J]. PLoS One, 2014, 9(2):e87113. doi: 10.1371/journal.pone.0087113 URL
[37]	Somaiah N, Beird HC, Barbo A, et al. Targeted next ge-neration sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations[J]. Oncotarget, 2018, 9(28):19891-19899. doi: 10.18632/oncotarget.24924 pmid: 29731991
[38]	Taylor BS, DeCarolis PL, Angeles CV, et al. Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas[J]. Cancer Discov, 2011, 1(7):587-597. doi: 10.1158/2159-8290.CD-11-0181 pmid: 22328974
[39]	Lam RCT, Johnson D, Lam G, et al. Clinical applications of circulating tumor-derived DNA in the management of gastrointestinal cancers - current evidence and future directions[J]. Front Oncol, 2022, 12:970242. doi: 10.3389/fonc.2022.970242 URL
[40]	Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications[J]. J Hematol Oncol, 2022, 15(1):131. doi: 10.1186/s13045-022-01351-y URL

Study on retroperitoneal liposarcoma: current status and challenge

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 40

Related Articles 5

Recommended Articles

Metrics

Comments

[1]	LIU Wenshuai, LU Weiqi, ZHOU Yuhong. Management of retroperitoneal sarcoma: rule, dilemma and perspectives-detailed interpretation of CSCO Guideline [J]. Journal of Surgery Concepts & Practice, 2022, 27(06): 483-489.
[2]	WANG Jian. Retroperitoneal tumor: pathological diagnosis and differential diagnosis [J]. Journal of Surgery Concepts & Practice, 2022, 27(06): 500-505.
[3]	WANG Zheng, BAO Cihang, JIANG Guoliang. Value of proton and heavy ion radiotherapy in treatment of retroperitoneal sarcoma [J]. Journal of Surgery Concepts & Practice, 2022, 27(06): 506-510.
[4]	PAN Xiangou, ZHANG Li, HOU Jiazhou, DU Shisuo, ZENG Zhaochong, WANG Binliang. Study on preoperative radiotherapy in conversion therapy for patients with primary retroperitoneal soft tissue sarcoma difficult to resect or unresectable [J]. Journal of Surgery Concepts & Practice, 2022, 27(06): 530-533.
[5]	ZHUANG Aobo, TONG Hanxing, ZHANG Yong, LU Weiqi, ZHOU Yuhong, LÜ Chentao. Safety analysis on surgical treatment of elderly patients with primary retroperitoneal soft tissue sarcoma: a retrospective cohort study [J]. Journal of Surgery Concepts & Practice, 2022, 27(06): 534-539.